NCT06417892 2026-04-21
Fruquintinib and Albumin-paclitaxel Combined With or Without PD-1 Antibody in 2nd-line Treatment of G/GEJ Adenocarcinoma
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Recruiting
Clinical Trials
8 trialsNCT04164199 2026-04-14
Study of Tislelizumab, Pamiparib, and Other Investigational Agents in Participants With Advanced Malignancies
BeOne Medicines
Phase 3 Active not recruiting
NCT07042685 2026-04-09
Trial of 5-Fluorouracil (5FU)-Based Therapy in Combination With Fruquintinib in Patients With Locally Advanced Unresectable or Metastatic Colorectal Cancer
The Methodist Hospital Research Institute
Phase 2 Recruiting
NCT07235293 2026-04-09
A Study to Test DSP107 in Combination With Atezolizumab in Comparison With Fruquintinib as a New Treatment for Colorectal Cancer.
Kahr Medical
Phase 2 Recruiting
NCT07515820 2026-04-07
SHR-3821 in Advanced Colorectal Cancer: an Exploratory Study
West China Hospital
Phase 2 Not yet recruiting
NCT07136077 2026-04-06
A Phase 2 Trial of Fruquintinib and Tislelizumab in ctDNA-defined Minimal Residual Disease in Colorectal Cancer After Completion of Adjuvant Chemotherapy
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT07510932 2026-04-06
FIRST-K
Korea University Anam Hospital
Phase 2 Not yet recruiting
NCT07502014 2026-03-30
A Clinical Study of Iparomlimab and Tuvonralimab Combined With Fruquintinib and Heterogeneous Radiotherapy Versus Fruquintinib as Third-Line and Subsequent-Line Treatment for Metastatic Colorectal Cancer
Huazhong University of Science and Technology
Phase 2 Not yet recruiting